Evidence map›Paper›PMID 39821801›Full record

ArticleGeroScience2025

Aβ42 biomarker linked to insula, striatum, thalamus and claustrum in dementia with Lewy bodies.

Vincent Gabriel, Olivier Bousiges, Mary Mondino, Benjamin Cretin, Nathalie Philippi, Candice Muller, Pierre Anthony, Catherine Demuynck, Paulo Loureiro de Sousa, Anne Botzung and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Cerebrospinal fluidAlzheimer's & dementia (New York, N. Y.)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vincent GabrielICube Laboratory UMR-7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team and IRIS Platform, University of Strasbourg and CNRS, Strasbourg, France. vincent.gabriel@etu.unistra.fr.ORCID 0009-0003-6107-4783
Olivier BousigesICube Laboratory UMR-7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team and IRIS Platform, University of Strasbourg and CNRS, Strasbourg, France.
Mary MondinoICube Laboratory UMR-7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team and IRIS Platform, University of Strasbourg and CNRS, Strasbourg, France.
Benjamin CretinICube Laboratory UMR-7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team and IRIS Platform, University of Strasbourg and CNRS, Strasbourg, France.
Nathalie PhilippiICube Laboratory UMR-7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team and IRIS Platform, University of Strasbourg and CNRS, Strasbourg, France.
Candice MullerCM2R (Centre de Mémoire Ressources Et Recherche), Geriatric Day Hospital and Neuropsychological Unit, Geriatrics Department and Neurology Service, University Hospital of Strasbourg, Strasbourg, France.
Pierre AnthonyCM2R (Centre de Mémoire Ressources Et Recherche), Geriatric Day Hospital and Neuropsychological Unit, Geriatrics Department and Neurology Service, University Hospital of Strasbourg, Strasbourg, France.
Catherine DemuynckCM2R (Centre de Mémoire Ressources Et Recherche), Geriatric Day Hospital and Neuropsychological Unit, Geriatrics Department and Neurology Service, University Hospital of Strasbourg, Strasbourg, France.
Paulo Loureiro de SousaICube Laboratory UMR-7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team and IRIS Platform, University of Strasbourg and CNRS, Strasbourg, France.
Anne BotzungICube Laboratory UMR-7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team and IRIS Platform, University of Strasbourg and CNRS, Strasbourg, France.
Léa SannaCM2R (Centre de Mémoire Ressources Et Recherche), Geriatric Day Hospital and Neuropsychological Unit, Geriatrics Department and Neurology Service, University Hospital of Strasbourg, Strasbourg, France.
Eléna ChabranICube Laboratory UMR-7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team and IRIS Platform, University of Strasbourg and CNRS, Strasbourg, France.
Frédéric BlancICube Laboratory UMR-7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS Team and IRIS Platform, University of Strasbourg and CNRS, Strasbourg, France.

Funding

Projet de Hospitalier de Recherche Clinique (PHRC) inter-régional IDRCB 2012-100992-41
6 · The paper itself

Abstract

The differential mechanisms between proteinopathies and neurodegeneration in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) remain unclear. To address this issue, we conducted a voxel-based morphometry and cerebrospinal fluid biomarker (α-synuclein, Aβ42, t-Tau and p-Tau

Indexed as

Amyloid beta-PeptidesLewy Body DiseasePeptide FragmentsAgedAged, 80 and overalpha-SynucleinAlzheimer DiseaseBiomarkersCorpus StriatumFemaleGray MatterHumansInsular CortexMagnetic Resonance ImagingMaleMiddle Agedalpha-SynucleinAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersPeptide Fragmentstau ProteinsAmyloidAβ42Cerebrospinal fluidDementia with Lewy bodiesVoxel-based morphometry

Identifiers

PMID39821801
PMCPMC12181484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.